Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease
EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and